company background image
4516

Nippon Shinyaku TSE:4516 Stock Report

Last Price

JP¥7.91k

Market Cap

JP¥532.8b

7D

-3.8%

1Y

-3.7%

Updated

07 Aug, 2022

Data

Company Financials +
4516 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance5/6
Financial Health6/6
Dividends4/6

4516 Stock Overview

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally.

Nippon Shinyaku Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nippon Shinyaku
Historical stock prices
Current Share PriceJP¥7,910.00
52 Week HighJP¥9,840.00
52 Week LowJP¥7,000.00
Beta0.19
1 Month Change-4.81%
3 Month Change-7.92%
1 Year Change-3.65%
3 Year Change-8.98%
5 Year Change10.94%
Change since IPO647.40%

Recent News & Updates

Shareholder Returns

4516JP PharmaceuticalsJP Market
7D-3.8%-2.1%0.5%
1Y-3.7%6.0%-0.09%

Return vs Industry: 4516 underperformed the JP Pharmaceuticals industry which returned 6% over the past year.

Return vs Market: 4516 underperformed the JP Market which returned -0.1% over the past year.

Price Volatility

Is 4516's price volatile compared to industry and market?
4516 volatility
4516 Average Weekly Movement6.6%
Pharmaceuticals Industry Average Movement4.1%
Market Average Movement3.9%
10% most volatile stocks in JP Market8.1%
10% least volatile stocks in JP Market2.1%

Stable Share Price: 4516 is more volatile than 75% of JP stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 4516's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.

About the Company

FoundedEmployeesCEOWebsite
19112,125Toru Nakaihttps://www.nippon-shinyaku.co.jp

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases.

Nippon Shinyaku Fundamentals Summary

How do Nippon Shinyaku's earnings and revenue compare to its market cap?
4516 fundamental statistics
Market CapJP¥532.76b
Earnings (TTM)JP¥24.99b
Revenue (TTM)JP¥137.48b

21.3x

P/E Ratio

3.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4516 income statement (TTM)
RevenueJP¥137.48b
Cost of RevenueJP¥50.19b
Gross ProfitJP¥87.29b
Other ExpensesJP¥62.31b
EarningsJP¥24.99b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 09, 2022

Earnings per share (EPS)370.97
Gross Margin63.49%
Net Profit Margin18.17%
Debt/Equity Ratio0%

How did 4516 perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

30%

Payout Ratio

Does 4516 pay a reliable dividends?

See 4516 dividend history and benchmarks
When do you need to buy 4516 by to receive an upcoming dividend?
Nippon Shinyaku dividend dates
Ex Dividend DateSep 29 2022
Dividend Pay DateDec 05 2022
Days until Ex dividend52 days
Days until Dividend pay date119 days

Does 4516 pay a reliable dividends?

See 4516 dividend history and benchmarks
We’ve recently updated our valuation analysis.

Valuation

Is 4516 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4516?

Other financial metrics that can be useful for relative valuation.

4516 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.4x
Enterprise Value/EBITDA12.8x
PEG Ratio3.4x

Price to Earnings Ratio vs Peers

How does 4516's PE Ratio compare to its peers?

4516 PE Ratio vs Peers
The above table shows the PE ratio for 4516 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average14.4x
4506 Sumitomo Pharma
5.3x-17.3%JP¥441.0b
4536 Santen Pharmaceutical
15.7x3.7%JP¥416.0b
4581 Taisho Pharmaceutical Holdings
24.7x5.1%JP¥437.0b
4540 Tsumura
11.9x10.5%JP¥239.1b
4516 Nippon Shinyaku
21.3x6.3%JP¥532.8b

Price-To-Earnings vs Peers: 4516 is expensive based on its Price-To-Earnings Ratio (21.3x) compared to the peer average (14.4x).


Price to Earnings Ratio vs Industry

How does 4516's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 4516 is expensive based on its Price-To-Earnings Ratio (21.3x) compared to the JP Pharmaceuticals industry average (17.4x)


Price to Earnings Ratio vs Fair Ratio

What is 4516's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4516 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.3x
Fair PE Ratio21.5x

Price-To-Earnings vs Fair Ratio: 4516 is good value based on its Price-To-Earnings Ratio (21.3x) compared to the estimated Fair Price-To-Earnings Ratio (21.5x).


Share Price vs Fair Value

What is the Fair Price of 4516 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4516 (¥7910) is trading below our estimate of fair value (¥19091.98)

Significantly Below Fair Value: 4516 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Nippon Shinyaku forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


6.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4516's forecast earnings growth (6.3% per year) is above the savings rate (0.04%).

Earnings vs Market: 4516's earnings (6.3% per year) are forecast to grow slower than the JP market (8.6% per year).

High Growth Earnings: 4516's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4516's revenue (4.1% per year) is forecast to grow slower than the JP market (4.4% per year).

High Growth Revenue: 4516's revenue (4.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 4516's Return on Equity is forecast to be low in 3 years time (12.7%).


Discover growth companies

Past Performance

How has Nippon Shinyaku performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


18.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 4516 has high quality earnings.

Growing Profit Margin: 4516's current net profit margins (18.2%) are higher than last year (17%).


Past Earnings Growth Analysis

Earnings Trend: 4516's earnings have grown by 18.4% per year over the past 5 years.

Accelerating Growth: 4516's earnings growth over the past year (20.7%) exceeds its 5-year average (18.4% per year).

Earnings vs Industry: 4516 earnings growth over the past year (20.7%) exceeded the Pharmaceuticals industry 17.2%.


Return on Equity

High ROE: 4516's Return on Equity (13.8%) is considered low.


Discover strong past performing companies

Financial Health

How is Nippon Shinyaku's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 4516's short term assets (¥149.7B) exceed its short term liabilities (¥32.0B).

Long Term Liabilities: 4516's short term assets (¥149.7B) exceed its long term liabilities (¥7.0B).


Debt to Equity History and Analysis

Debt Level: 4516 is debt free.

Reducing Debt: 4516 has not had any debt for past 5 years.

Debt Coverage: 4516 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 4516 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Nippon Shinyaku current dividend yield, its reliability and sustainability?

Dividend Score

4/6

Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


1.42%

Current Dividend Yield

Upcoming Dividend Payment

TodayAug 08 2022Ex Dividend DateSep 29 2022Dividend Pay DateDec 05 202267 days from Ex DividendBuy in the next 52 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 4516's dividend (1.42%) isn’t notable compared to the bottom 25% of dividend payers in the JP market (1.63%).

High Dividend: 4516's dividend (1.42%) is low compared to the top 25% of dividend payers in the JP market (3.62%).


Stability and Growth of Payments

Stable Dividend: 4516's dividends per share have been stable in the past 10 years.

Growing Dividend: 4516's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (29.7%), 4516's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonable cash payout ratio (61%), 4516's dividend payments are covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Toru Nakai (51 yo)

1.17yrs

Tenure

Mr. Toru Nakai serves as the President of Nippon Shinyaku Co., Ltd. since June 2021 and served as its Head of Global Business Division since 2019 until June 2021 and serves as its Director at since June 20...


Leadership Team

Experienced Management: 4516's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: 4516's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Nippon Shinyaku Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Nippon Shinyaku Co., Ltd.
  • Ticker: 4516
  • Exchange: TSE
  • Founded: 1911
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: JP¥532.763b
  • Shares outstanding: 67.35m
  • Website: https://www.nippon-shinyaku.co.jp

Number of Employees


Location

  • Nippon Shinyaku Co., Ltd.
  • 14, Nishinosho-Monguchi-cho
  • Kisshoin
  • Kyoto
  • 601-8550
  • Japan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/07 00:00
End of Day Share Price2022/08/05 00:00
Earnings2022/03/31
Annual Earnings2022/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.